Clinical Trial Update: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Orforglipron (LY3502970) versus semaglutide in adults with Type 2 diabetes mellitus inadequately controlled with metformin has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Orforglipron (orforglipron)
• semaglutide (semaglutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED